Consistent with our observation in HPV-negative HNSCC cell lines, changes to EGFR expression after cetuximab treatment have greater variability in tumors with low CDKN2A expression than high expression (Figure 6C). This evidence concerns the gene CDKN2A and head and neck squamous cell carcinoma.